Revolution Medicines (RVMD) Change in Accured Expenses (2019 - 2026)

Revolution Medicines' Change in Accured Expenses history runs 8 years deep, the most recent figure standing at -$16.7 million for Q1 2026.

• On a quarterly basis, Change in Accured Expenses fell 1180.63% year-over-year to -$16.7 million in Q1 2026; TTM through Mar 2026 was $94.0 million, a 109.81% increase from a year earlier, with the FY2025 full-year figure at $112.3 million, up 410.65% from the prior year.
• Change in Accured Expenses fell to -$16.7 million in Q1 2026 per RVMD's latest filing, from $54.6 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $54.6 million in Q4 2025 and bottomed at -$21.3 million in Q1 2024.
• The 5-year median for Change in Accured Expenses is $7.6 million (2023), against an average of $7.9 million.
• Across the five-year window, Change in Accured Expenses soared 685.1% in 2023 and plunged 1180.63% in 2026, its largest moves.
• Year by year, Change in Accured Expenses stood at -$3.0 million in 2022, then plunged by 112.1% to -$6.3 million in 2023, then soared by 390.86% to $18.3 million in 2024, then soared by 198.42% to $54.6 million in 2025, then plunged by 130.66% to -$16.7 million in 2026.
• Per Business Quant, the three latest RVMD Change in Accured Expenses figures stand at -$16.7 million (Q1 2026), $54.6 million (Q4 2025), and $45.3 million (Q3 2025).